These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37793784)

  • 21. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.
    Phuc NM; Wu Z; O Y; Lee JH; Oh S; Song GY; Liu KH
    Drug Metab Dispos; 2017 Jul; 45(7):765-769. PubMed ID: 28461575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver.
    Yang TJ; Sai Y; Krausz KW; Gonzalez FJ; Gelboin HV
    Pharmacogenetics; 1998 Oct; 8(5):375-82. PubMed ID: 9825829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
    Tracy TS; Marra C; Wrighton SA; Gonzalez FJ; Korzekwa KR
    Biochem Pharmacol; 1996 Oct; 52(8):1305-9. PubMed ID: 8937439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Recognition in Mitochondrial Cytochromes P450 That Catalyze the Terminal Steps of Corticosteroid Biosynthesis.
    Peng HM; Auchus RJ
    Biochemistry; 2017 May; 56(17):2282-2293. PubMed ID: 28355486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
    Shimada T; Mernaugh RL; Guengerich FP
    Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s.
    Waxman DJ; Lapenson DP; Aoyama T; Gelboin HV; Gonzalez FJ; Korzekwa K
    Arch Biochem Biophys; 1991 Oct; 290(1):160-6. PubMed ID: 1898086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
    Murray M
    Clin Pharmacokinet; 1992 Aug; 23(2):132-46. PubMed ID: 1511529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
    Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
    Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial P450s.
    Omura T
    Chem Biol Interact; 2006 Oct; 163(1-2):86-93. PubMed ID: 16884708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
    Kim S; Choi WG; Kwon M; Lee S; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31430908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
    Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
    Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes.
    Shimada T; Takenaka S; Murayama N; Yamazaki H; Kim JH; Kim D; Yoshimoto FK; Guengerich FP; Komori M
    Chem Res Toxicol; 2015 Feb; 28(2):268-78. PubMed ID: 25642975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.
    Ortiz de Montellano PR
    J Inorg Biochem; 2018 Mar; 180():235-245. PubMed ID: 29352597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.
    Lindmark B; Lundahl A; Kanebratt KP; Andersson TB; Isin EM
    Br J Pharmacol; 2018 Jun; 175(11):2116-2129. PubMed ID: 29574682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.
    Patten CJ; Smith TJ; Friesen MJ; Tynes RE; Yang CS; Murphy SE
    Carcinogenesis; 1997 Aug; 18(8):1623-30. PubMed ID: 9276639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
    Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
    Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
    Masubuchi Y; Horie T
    Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes.
    McLean KJ; Marshall KR; Richmond A; Hunter IS; Fowler K; Kieser T; Gurcha SS; Besra GS; Munro AW
    Microbiology (Reading); 2002 Oct; 148(Pt 10):2937-2949. PubMed ID: 12368427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.